InNexus
Biotechnology Inc., (TSX: IXS.V; OTC Bulletin Board: IXSBF)
(ixsbio), a drug development company commercializing the
next generation of monoclonal antibodies based on its Dynamic Cross Linking
(DXL(TM)) technology, announced that it has launched a large scale
primate study of DXL625 (CD20), the company's lead program.
"We are beginning a study in cynomolgus monkeys of DXL625, an antibody
directed against the B-cell marker CD20 and enhanced in potency with our
DXL(TM) technology," said Thomas Kindt, Ph.D., Chief Scientific Officer.
"The test is designed to evaluate toxicity and pharmokinetics of our
product and to measure B-cell depletion and recovery in this primate
species. This study, which takes multiple months to complete and is part of
our drug development plan will generate data moving us toward human
clinical trial testing with DXL625."
"Our scientific team has made steady progress in the rapid development
of our first preclinical candidate, DXL625 for the prospective treatment of
Non-Hodgkin's Lymphoma," said Jeff Morhet, CEO and Chairman. "The primate
study is being conducted by Covance Inc. within their world-class
facilities in Wisconsin. The launch of this study marks a significant
milestone achievement for the company and our lead product DXL625."
InNexus recently announced the addition of a new product designated
DXLr120 (CD20). This is the third product added to the growing InNexus
pipeline and was developed using new recombinant methods to produce a
DXL(TM) anti-CD20 antibody. Upon questions regarding InNexus having a
franchise of CD20 products using multiple methods of creation, chemical and
recombinant, CEO Morhet said, "I would also think that these products could
and should be bundled toward future collaborations with pharmaceutical
companies and DXLr120 was developed within our partnership with Royalty
Pharma."
About InNexus
InNexus is a drug development company commercializing the next
generation of monoclonal antibodies based on its DXL(TM) technology, which
improves the potency of existing antibody products while opening new
markets and disease applications. DXL(TM) antibodies utilize unique, novel
and patented methods and technologies of InNexus.
InNexus is headquartered in British Columbia with principal management
based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own
in-house developmental facilities. These development resources provide
validation of protein and peptide discoveries, enabling InNexus (and its
strategic partners) to advance novel drug therapeutics and diagnostics. To
learn more about InNexus, please visit ixsbio.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this news release. This news
release may contain assumptions, estimates, and other forward-looking
statements that involve inherent risks and uncertainties and are subject to
factors, many of which are beyond the Company's control, that may cause
actual results or performance to differ materially from those currently
anticipated in such statements.
InNexus Biotechnology Inc.
ixsbio